Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19
Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19
复制标题
DOI：
10.1111/hepr.13551
复制
发表时间：
2020-08-14
影响因子：
4.2
通讯作者：
Sakamoto, Naoya
中科院分区：
文献类型：
--
作者：
Suda, Goki;Ogawa, Koji;Sakamoto, Naoya
目的2019冠状病毒病（COVID-19）是一个严重的公共卫生问题，在日本的流行情况尚不清楚。伴随肝病可能会增加COVID-19疾病的严重程度，慢性肝病患者有时需要频繁住院和胃肠道内窥镜检查。因此，明确肝病门诊患者中无症状COVID-19的患病率对于预防院内感染至关重要。我们旨在阐明在日本经历第二波COVID-19的地区，无COVID-19症状的肝病门诊患者中COVID-19血清阳性率的时间依赖性变化。方法我们分别从2019年5月、2020年3月和2020年5月收集了100例、300例和300例连续肝病门诊患者的保存血清，这些患者均无COVID-19症状。通过免疫色谱法分析血清以检测针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）（KURABO）的免疫球蛋白G，并通过Elecsys Anti-SARS-CoV-2-assay（Roche Diagnostics）进行分析。结果分析了2019年5月COVID-19大流行前的100例病例，结果显示免疫层析检测和Elecsys的特异性分别为98%（95%置信区间[CI]，93-99.8%）和100%（95% CI，97-100%）。对2020年3月以来300例病例的分析显示，Elecsys抗SARS-CoV-2检测的COVID-19血清阳性率为0. 3%（1/300; 95% CI，0- 1. 8%）。对2020年5月以来的300例病例的分析显示血清阳性率为0%（0/300; 95%CI，0-1.0%）。结论Elecsys抗SARS-CoV-2检测方法具有较高的特异性。截至2020年5月，在札幌的肝病门诊患者中，通过Elecsys抗SARS-CoV-2检测，COVID-19的累积血清阳性率为0.17%（1/600; 95%CI，0.0-0.9%）。
Aim Coronavirus disease 2019 (COVID-19) is a serious public health concern, with unclarified prevalence in Japan. Concomitant liver disease could increase the severity of COVID-19 disease, and chronic liver disease patients sometimes require frequent admission and gastrointestinal endoscopy. Thus, clarifying the prevalence of asymptomatic COVID-19 in outpatients with liver disease is essential for preventing nosocomial infections. We aimed to clarify the time-dependent changes in COVID-19 seroprevalence in liver disease outpatients, who were asymptomatic for COVID-19, in an area of Japan experiencing a second wave of COVID-19. Methods We included the preserved sera of 100, 300, and 300 consecutive liver disease outpatients, who were asymptomatic for COVID-19, from May 2019, March 2020, and May 2020, respectively. The sera were analyzed immunochromatographically to detect immunoglobulin G against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (KURABO) and by Elecsys Anti-SARS-CoV-2-assay (Roche Diagnostics). Results Analysis of 100 cases from May 2019, before COVID-19 became pandemic, revealed that the specificity of immunochromatographic tests and Elecsys were 98% (95% confidence interval [CI], 93-99.8%) and 100% (95% CI, 97-100%), respectively. Analysis of 300 cases from March 2020 revealed a seroprevalence of 0.3% (1/300; 95% CI, 0-1.8%) for COVID-19 by Elecsys Anti-SARS-CoV-2 assay. Analysis of 300 cases from May 2020 revealed a seroprevalence of 0% (0/300; 95% CI, 0-1.0%). Conclusions The Elecsys Anti-SARS-CoV-2 assay has high specificity. The cumulative seroprevalence of COVID-19 by the Elecsys Anti-SARS-CoV-2 assay in outpatients with liver disease in Sapporo, who were asymptomatic for COVID-19, was 0.17% (1/600; 95% CI, 0.0-0.9%) until May 2020.